(VIRI) – Company Press Releases
-
Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID
-
Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
-
Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones
-
Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID
-
Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID
-
Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
-
Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023
-
Virios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023
-
Virios Therapeutics Announces Termination of At-The-Market Sales Agreement
-
Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023
-
Virios Therapeutics Announces Halt to At-The-Market Offering Sales
-
Virios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
-
Virios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a New Treatment Option for Fibromyalgia
-
Virios Therapeutics to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023
-
Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Labe
-
Virios Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
-
Virios Therapeutics Announces Submission of Final Toxicology Results to Support Proposed Phase 3 Program for Novel Therapy to Treat Fibromyalgia
-
Virios Therapeutics Announces First Quarter 2023 Financial Results
-
Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023
-
Virios Therapeutics Announces Initial FDA Feedback on Proposed IMC-1 Phase 3 Program for Treatment of Fibromyalgia
-
Virios Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results
-
Virios Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14, 2023
-
Virios Therapeutics Announces Exploratory Long-COVID Trial Top-Line Data, Featuring Combination of Valacyclovir and Celecoxib, Projected in June 2023
-
Virios Therapeutics Announces Scheduling of FDA Meeting in March 2023 to Discuss IMC-1 Fibromyalgia Phase 3 Program
-
Virios Therapeutics, Inc. to Present at the Virtual Planet MicroCap Showcase
-
Virios Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update
-
Virios Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Monday, November 14, 2022
-
Virios Therapeutics, Inc. Announces Closing of Public Offering
-
Virios Therapeutics, Inc. Announces Pricing of Public Offering
-
Virios Therapeutics, Inc. Announces Proposed Public Offering
-
Virios Therapeutics Announces Top-Line Results from Phase 2b Study of IMC-1 in Fibromyalgia
-
New to The Street TV / Newsmax TV Announces its Eight Interviews on This Week's TV Broadcast, Episode #386, September 18, 2022, 10-11 AM ET
-
New to The Street TV Announces Four Corporate Interviews on its 384th TV Show, Airing on the Fox Business Network, Tonight, Monday, September 12, 2022, at 10:30 PM PT
-
Virios Therapeutics’ Announces Dosing of First Patient in IMC-2 Long-COVID Treatment Trial
-
Virios Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update
-
Virios Therapeutics, Inc. to Present at Investor Summit Group’s Q3 Virtual Conference
-
Virios Therapeutics: The 'Virus Hypothesis' That Stands to Change the Lives of 10M Americans
-
Virios Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on Thursday, August 11, 2022
-
Virios Therapeutics (Nasdaq: VIRI) Advancing Potential Paradigm Shift in Fibromyalgia Treatment
-
Virios' Promising Fibromyalgia Treatment Candidate Expects September 2022 Phase 2b Results
-
Virios Therapeutics’ Study Featured in Peer-Reviewed Journal Publication Highlighting Association of Herpes Simplex Type 1 Viral Infection with Common Gastrointestinal Disorders, Including in Patien
-
Virios Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update
-
Virios Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on Thursday, May 12, 2022
-
Virios Therapeutics Completes Enrollment of 425 Patients in Phase 2b “FORTRESS” Clinical Trial for Fibromyalgia
-
Virios Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
-
Virios Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update on Thursday, March 17, 2022
-
Virios Therapeutics to Present at the 34th Annual Roth Conference on Monday, March 14, 2022
-
Virios Therapeutics Announces Research Collaboration Exploring the Potential of Combination Antiviral Therapy for Treating Long COVID
-
RedChip Partners with Benzinga to Host Exclusive Small-Cap CEO Interview Series on January 28
-
Virios Therapeutics to Present at the Virtual H.C. Wainwright BioConnect Conference
Back to VIRI Stock Lookup
